Company intelligence / Profile preview
Starna Therapeutics
Suzhou, Jiangsu, Chinastarnatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Starna Therapeutics has developed proprietary extrahepatic targeted delivery technology for RNA-based drugs. Their lead preventive vaccine program is expected to enter the clinic in 2024. The company leverages its STAR LNP platform for precise organ and cell targeting, with a focus on next-generation mRNA and circRNA therapies. No published human efficacy data yet.[1][5]
- Therapeutic areas
- Infectious Diseases
- Modalities
- mRNAcircular RNA (circRNA)linear mRNALNP (Lipid Nanoparticle) delivery systemsGeneral RNA-based modalities[1][5]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Starna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Starna Therapeutics.